Financhill
Sell
37

SBIO Quote, Financials, Valuation and Earnings

Last price:
$34.20
Seasonality move :
-5.06%
Day range:
$33.65 - $34.42
52-week range:
$31.00 - $42.73
Dividend yield:
3.41%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
11.8K
Avg. volume:
14.9K
1-year change:
3.52%
Market cap:
--
Revenue:
--
EPS (TTM):
--

Analysts' Opinion

  • Consensus Rating
    ALPS Medical Breakthroughs ETF has received a consensus rating of --. The company's average rating is a -- based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
  • Price Target Downside
    According to analysts' consensus price target of --, ALPS Medical Breakthroughs ETF has an estimated downside of -- from its current price of $34.41.
  • Price Target Upside
    According to analysts, the highest upside price target is -- representing -100% upside increase from its current price of $34.41.

Fair Value

  • According to the consensus of 0 analysts, ALPS Medical Breakthroughs ETF has -- downside to fair value with a price target of -- per share.

SBIO vs. S&P 500

  • Over the past 5 trading days, ALPS Medical Breakthroughs ETF has overperformed the S&P 500 by 1.7% suggesting its relative strength compared to the major market average is strong at this time.

Share Buyback

  • ALPS Medical Breakthroughs ETF does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.

Revenue Growth

  • ALPS Medical Breakthroughs ETF has grown year-over-year revenues for 0 quarters straight. In the most recent quarter ALPS Medical Breakthroughs ETF reported revenues of --.

Earnings Growth

  • ALPS Medical Breakthroughs ETF has grown year-over-year earnings for 0 quarters straight. In the most recent quarter ALPS Medical Breakthroughs ETF reported earnings per share of --.
Enterprise value:
--
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
--
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
Trailing 12 Months Fiscal Quarters
Period Ending 2022-12-27 2023-12-27 2023-12-27
Income Statement
Revenue -- -- -- -- --
Gross Profit -- -- -- -- --
Operating Income -- -- -- -- --
EBITDA -- -- -- -- --
Diluted EPS -- -- -- -- --
Period Ending 2020-12-27 2021-12-27 2022-12-27 2023-12-27
Balance Sheet
Current Assets -- -- -- -- --
Total Assets -- -- -- -- --
Current Liabilities -- -- -- -- --
Total Liabilities -- -- -- -- --
Total Equity -- -- -- -- --
Total Debt -- -- -- -- --
Trailing 12 Months Fiscal Quarters
Period Ending 2022-12-27 2023-12-27 2023-12-27
Cash Flow Statement
Cash Flow Operations -- -- -- -- --
Cash From Investing -- -- -- -- --
Cash From Financing -- -- -- -- --
Free Cash Flow -- -- -- -- --
SBIO
Sector
Market Cap
--
--
Price % of 52-Week High
80.53%
--
Dividend Yield
3.41%
--
Shareholder Yield
--
--
1-Year Price Total Return
3.52%
--
Beta (5-Year)
0.889
--
Dividend yield:
3.41%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Technicals

8-day SMA
Sell
Level $34.66
200-day SMA
Sell
Level $35.92
Bollinger Bands (100)
Sell
Level 35.69 - 39.23
Chaikin Money Flow
Buy
Level 4.2M
20-day SMA
Sell
Level $36.80
Relative Strength Index (RSI14)
Sell
Level 37.35
ADX Line
Buy
Level 8.33
Williams %R
Neutral
Level -73.4963
50-day SMA
Sell
Level $38.13
MACD (12, 26)
Sell
Level -1.22
25-day Aroon Oscillator
Sell
Level -60
On Balance Volume
Neutral
Level 2.4M

Financial Scores

--
Altman Z-Score (Annual)
Level (--)
--
CA Score (Annual)
Level (--)
--
Beneish M-Score (Annual)
Level (--)
Buy
Momentum Score
Level (9)
--
Ohlson Score
Level (--)
--
Piotroski F Score (Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)

Revenue Forecast

Earnings per Share Forecast

Stock Forecast FAQ

In the current month, SBIO has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The SBIO average analyst price target in the past 3 months is --.

  • Where Will ALPS Medical Breakthroughs ETF Stock Be In 1 Year?

    According to analysts, the consensus estimate is that ALPS Medical Breakthroughs ETF share price will drop to -- per share over the next 12 months.

  • What Do Analysts Say About ALPS Medical Breakthroughs ETF?

    Analysts are divided on their view about ALPS Medical Breakthroughs ETF share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that ALPS Medical Breakthroughs ETF is a Sell and believe this share price will rise from its current level to --.

  • What Is ALPS Medical Breakthroughs ETF's Price Target?

    The price target for ALPS Medical Breakthroughs ETF over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.

  • Is SBIO A Buy, Sell Or Hold?

    According to Wall Street analysts, the consensus rating for ALPS Medical Breakthroughs ETF is a --. 0 of 0 analysts rate the stock a -- at this time.

  • How Can I Buy Shares Of SBIO?

    You can purchase shares of ALPS Medical Breakthroughs ETF via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase ALPS Medical Breakthroughs ETF shares.

  • What Is The ALPS Medical Breakthroughs ETF Share Price Today?

    ALPS Medical Breakthroughs ETF was last trading at $34.20 per share. This represents the most recent stock quote for ALPS Medical Breakthroughs ETF. Yesterday, ALPS Medical Breakthroughs ETF closed at $34.41 per share.

  • How To Buy ALPS Medical Breakthroughs ETF Stock Online?

    In order to purchase ALPS Medical Breakthroughs ETF stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is AMD Stock an All-Time Buy?
Is AMD Stock an All-Time Buy?

Advanced Micro Devices (NASDAQ:AMD) is a high-growth AI stock that…

How High Will Airbnb Stock Go?
How High Will Airbnb Stock Go?

Airbnb, Inc. (NASDAQ:ABNB) share price has seen substantial turbulence over…

Why Is SoundHound AI Stock Up So Much?
Why Is SoundHound AI Stock Up So Much?

Like many companies improving AI technologies and exploring ways to…

Stock Ideas

Buy
65
Is AAPL Stock a Buy?

Market Cap: $3.9T
P/E Ratio: 43x

Buy
56
Is NVDA Stock a Buy?

Market Cap: $3.4T
P/E Ratio: 117x

Buy
57
Is MSFT Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 37x

Alerts

Buy
64
ARQQ alert for Dec 27

Arqit Quantum [ARQQ] is down 6.68% over the past day.

Buy
64
QMCO alert for Dec 27

Quantum [QMCO] is down 1.14% over the past day.

Buy
65
ALGS alert for Dec 27

Aligos Therapeutics [ALGS] is down 3.16% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock